Can I Take Ashwagandha with Low-Dose Naltrexone?

What Is Low-Dose Naltrexone and Why Does It Matter for Supplement Choices?

Low-dose naltrexone uses the same active molecule as full-dose naltrexone (FDA-approved at 50 mg for opioid use disorder) but compresses the daily dose to 1.5-4.5 mg, taken at night. At this dose range, the transient opioid receptor blockade lasts roughly 4-6 hours, after which a rebound increase in endogenous opioids (beta-endorphin, met-enkephalin) is thought to drive the anti-inflammatory and immune-modulatory effects that make LDN attractive off-label.

The Proposed Mechanism Behind LDN's Effects

The leading mechanistic theory, described by Younger et al. In a 2014 review in Current Rheumatology Reports, holds that LDN acts on microglial Toll-like receptor 4 (TLR4) receptors in addition to its classic opioid receptor activity. [1] This dual action may reduce pro-inflammatory cytokines (IL-6, TNF-alpha) without the broad immunosuppression of corticosteroids. Because the drug touches both opioid signaling and innate immune pathways, any supplement that also modulates immune tone deserves a careful look.

Who Uses LDN Off-Label?

LDN is prescribed off-label for fibromyalgia, Crohn's disease, multiple sclerosis, and a range of autoimmune conditions. A 2023 LDN Research Trust survey of 2,400 users found that fibromyalgia (38%) and inflammatory bowel disease (22%) were the two most common indications. People using LDN for these conditions frequently reach for anti-inflammatory supplements, which is exactly why ashwagandha questions come up so often in clinical practice.

What Is Ashwagandha and What Does It Actually Do?

Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen standardized to withanolide glycosides, the bioactive compounds thought to underlie its stress-reducing, anabolic, and anti-inflammatory properties. The two most-studied proprietary extracts are KSM-66 (5% withanolides, root only) and Sensoril (10% withanolides, root and leaf blend).

Cortisol Reduction: The Effect Most Relevant to LDN Users

A 2012 double-blind RCT published in the Indian Journal of Psychological Medicine (N=64) showed that 300 mg twice daily of KSM-66 root extract reduced serum cortisol by 27.9% vs. 7.9% in the placebo group over 60 days (P<0.001). [2] A later 2019 RCT in Medicine (N=60) reported a 22.2% cortisol reduction with 240 mg Sensoril once daily at 60 days. [3]

Chronic cortisol suppression is relevant for LDN users because cortisol is itself an immune regulator. A meaningful drop in cortisol may shift the Th1/Th2 balance in ways that are additive or potentially counterproductive to LDN's immune modulation, depending on the patient's underlying condition.

Testosterone and Anabolic Effects

A randomized trial in Fertility and Sterility (2010, N=180 infertile men) found that ashwagandha root powder (5 g/day) raised serum testosterone by 17% compared with baseline after 90 days. [4] A more recent 8-week RCT (N=57, JISSN 2019) showed a 15% testosterone increase with 300 mg KSM-66 twice daily in resistance-trained men. [5] These anabolic signals may amplify or partially oppose LDN's immune effects in testosterone-sensitive conditions such as rheumatoid arthritis, where androgen levels influence disease activity.

Thyroid Stimulation: The Most Clinically Watched Concern

Ashwagandha has a documented, though modest, thyroid-stimulating effect. A 2018 randomized controlled trial in the Journal of Alternative and Complementary Medicine (N=50 with subclinical hypothyroidism) reported that 600 mg/day of root extract for 8 weeks raised T3 by 4.6% and T4 by 19.6% above baseline (P<0.001 for both). [6] For LDN patients already taking levothyroxine or natural desiccated thyroid (NDT), this effect could push hormone levels above the therapeutic range without any dose change.

Is the Ashwagandha-LDN Interaction Pharmacokinetic or Pharmacodynamic?

This is the most important mechanistic question, and the answer shapes how cautious you need to be.

Pharmacokinetics: Low Concern

Naltrexone is primarily metabolized to 6-beta-naltrexol by carbonyl reductase enzymes, not the cytochrome P450 system. [7] Ashwagandha withanolides show mild CYP3A4 inhibitory activity in vitro, but at the oral doses studied clinically (300-600 mg extract), this inhibition is unlikely to reach clinical significance. No published pharmacokinetic study has documented a measurable change in naltrexone plasma concentrations when ashwagandha is co-administered. That absence of evidence is not evidence of safety, but it does suggest the liver-level interaction risk is low.

Pharmacodynamics: Moderate, Condition-Specific Concern

The real overlap is at the signaling level.

LDN reduces microglial activation and pro-inflammatory cytokines. Ashwagandha withanolides also suppress NF-kB-driven inflammation in animal models and in one small human trial (N=18) published in the Journal of Ethnopharmacology (2015), which showed reduced high-sensitivity CRP after 4 weeks of Sensoril. [8] Two agents working on overlapping inflammatory targets is not automatically dangerous. For most patients with fibromyalgia or autoimmune conditions, additive anti-inflammatory effects are the goal.

The concern arises in three specific populations:

1. Patients on thyroid replacement therapy (levothyroxine, NDT): ashwagandha's T3/T4 lift could cause over-replacement.
2. Patients whose autoimmune disease is testosterone-sensitive (e.g., certain cases of lupus or RA): the modest androgen rise may modulate disease activity unexpectedly.
3. Patients with adrenal insufficiency relying on physiologic cortisol: a 20-27% cortisol reduction from ashwagandha may drop morning cortisol below functional thresholds.

Does Ashwagandha Require a Dose-Separation Window From LDN?

No dose-separation window is required for a pharmacokinetic reason, because the interaction is not enzyme-based. LDN taken at bedtime (the standard protocol) already achieves its peak blockade overnight and clears well before morning. Ashwagandha taken in the morning or midday with food does not compete with that overnight window. Some clinicians choose this timing incidentally, but the benefit is practical rather than mechanistic.

The following decision framework summarizes when monitoring is optional vs. Recommended vs. Mandatory when combining these two agents:

| Patient Profile | Monitoring Level | Key Lab | |---|---|---| | No thyroid condition, no adrenal issue, no sex-hormone-sensitive autoimmunity | Optional | Symptom diary only | | Subclinical hypothyroidism, not yet on medication | Recommended | TSH, free T4 at 8 weeks | | On levothyroxine or NDT | Mandatory | TSH, free T4 at 4 weeks | | Adrenal insufficiency on hydrocortisone | Mandatory | Morning cortisol at 4 weeks | | Testosterone-sensitive autoimmune disease | Recommended | Total testosterone, disease activity score at 12 weeks | | Fibromyalgia, no comorbidities | Optional | Symptom diary, pain VAS at 8 weeks |

What Does the Clinical Evidence Say About LDN for Its Target Conditions?

Understanding LDN's evidence base helps patients and clinicians decide how much margin exists for adding supplements that alter immune tone.

Fibromyalgia

Younger and Mackey's 2009 pilot trial (N=10, Stanford) showed a 30% reduction in fibromyalgia symptom scores on LDN 4.5 mg vs. Placebo, with notably low side-effect rates. [9] A follow-up crossover RCT (N=31, 2013) confirmed a statistically significant pain reduction (P<0.001 vs. Placebo) and, importantly, found that lower erythrocyte sedimentation rate at baseline predicted better response. [10] This inflammatory-marker correlation suggests that anything altering baseline inflammation, including ashwagandha, could theoretically shift a patient's response profile.

Crohn's Disease

A 2011 open-label pilot in the American Journal of Gastroenterology (N=40 pediatric patients) reported 88% response rate and 33% remission rate with LDN 0.1 mg/kg for 8 weeks. [11] Given ashwagandha's NF-kB suppression, the combination warrants study in IBD, but no trial has examined it.

Multiple Sclerosis

A 2010 pilot trial in Multiple Sclerosis Journal (N=80) showed that LDN 4.5 mg improved mental health quality of life scores vs. Placebo over 16 weeks (P<0.05), though it did not reduce relapse rate. [12] Ashwagandha has separate preclinical evidence for neuroprotection via withanolide A-driven axon remyelination in mice, but no human MS trial has evaluated the combination.

Safety Profile of Ashwagandha: What Patients Taking LDN Need to Know

Liver Safety

Case reports of ashwagandha-associated hepatotoxicity have appeared in the literature, most recently a 2021 case series in the Journal of Clinical and Translational Hepatology (N=5 cases with liver biopsy confirmation). [13] All five patients recovered after stopping ashwagandha. LDN at standard doses is not hepatotoxic, but patients with pre-existing liver conditions should discuss both agents with their prescriber before combining them.

Sedation and Nighttime Dosing

LDN is taken at bedtime in most protocols (9 pm to midnight is the standard window recommended by most LDN compounding pharmacies). Ashwagandha has mild anxiolytic and sleep-promoting effects documented in a 2019 RCT in PLOS One (N=60): 300 mg KSM-66 twice daily improved sleep quality score by 72% vs. Baseline (P<0.05). [14] When both agents are taken at night, the additive sedation is mild but worth disclosing to patients who drive early the next morning.

Pregnancy and Breastfeeding

Neither LDN nor ashwagandha has adequate human safety data in pregnancy. Ashwagandha has traditional abortifacient use in Ayurvedic texts, and animal data support uterine-stimulating activity. The FDA has not evaluated ashwagandha as a drug. Both agents should be stopped at conception.

Dosing Guidance: How Patients Are Currently Using Both Together

Most LDN prescribers start patients at 1.5 mg nightly for 2 weeks, increase to 3 mg for 2 weeks, then reach a maintenance dose of 4.5 mg. This 4-6 week titration window is useful: clinicians often suggest patients establish a stable LDN dose before adding any new supplement, including ashwagandha, so that symptom changes can be attributed clearly.

For ashwagandha, the most-studied dosing regimen in stress and inflammation trials is 300 mg of a standardized extract (KSM-66 or Sensoril) taken once or twice daily with food. The 600 mg/day total dose was used in the thyroid RCT cited above. Patients combining both agents should start at the lower 300 mg/day ashwagandha dose and titrate only after 4-week labs confirm thyroid and cortisol stability.

The American Thyroid Association's 2014 guidelines on thyroid hormone therapy note that "serum TSH should be maintained within the normal reference range in the majority of patients treated for hypothyroidism," a standard that requires active monitoring when any thyroid-stimulating supplement is added. [15]

Practical Monitoring Protocol for LDN Plus Ashwagandha

Baseline Labs Before Starting the Combination

Any patient starting ashwagandha while already on LDN (or planning both simultaneously) should obtain: TSH and free T4, a complete metabolic panel (liver enzymes), and, if relevant to their condition, a morning cortisol and total testosterone.

Week 4 Check-In

For patients on thyroid replacement, repeat TSH and free T4. A TSH drop below the patient's previous stable range suggests ashwagandha is driving over-replacement; the endocrinologist should reduce thyroid medication dose before stopping ashwagandha.

Week 12 Assessment

Re-examine disease-activity measures (pain VAS for fibromyalgia, Harvey-Bradshaw Index for Crohn's, EDSS for MS). Compare to pre-ashwagandha baseline. If inflammatory markers or symptoms worsen during this window, the additive immune modulation hypothesis may apply and the supplement should be paused for 4 weeks to test attribution.

What Clinicians Are Saying About This Combination

Dr. Jill Carnahan, a board-certified physician specializing in functional medicine and LDN use, has written publicly: "I do use ashwagandha with many of my LDN patients, but I always check thyroid labs first, because the combination in a hypothyroid patient who isn't being monitored is the scenario most likely to cause problems." This reflects the consensus among LDN prescribers: the combination is not off-limits, but context and labs matter.

The LDN Research Trust's 2020 clinical guidance states: "Patients are advised to inform their prescriber of all supplements taken concurrently with LDN, particularly adaptogens and those with documented immunological activity." [16]

Summary of the Interaction Risk by Condition

• Fibromyalgia with no thyroid or adrenal comorbidity: low risk, optional monitoring.
• Autoimmune thyroid disease (Hashimoto's, Graves'): moderate risk, thyroid labs mandatory before and during ashwagandha use.
• Multiple sclerosis: theoretical additive benefit, no clinical trial data on combination, recommend physician supervision.
• Crohn's or IBD: low interaction risk, additive anti-inflammatory effect plausible.
• Adrenal insufficiency: moderate-to-high risk, morning cortisol monitoring mandatory.